Related Experiment Video
Updated: Aug 5, 2026
Use of the Operant Orofacial Pain Assessment Device (OPAD) to Measure Changes in Nociceptive Behavior
Published on: June 10, 2013
Orexinergic-Opioidergic Interactions Within the Nucleus Accumbens in the Modulation of Acute Pain: Evidence From the
Mohammad Sajad Jolani1,2, Mahsa Mohammadi2,3, Roghayeh Mozafari4
1School of Medicine, Tehran University of Medical Sciences, 1417613151 Tehran, Iran.
Background:
The nucleus accumbens (NAc) plays a central role in integrating motivational, reward-related, and nociceptive inputs. Opioid and orexin systems within the NAc are both implicated in pain modulation, yet their functional interaction in acute nociception is not fully understood. This study examined the interplay between opioidergic and orexinergic signaling in the NAc during acute pain processing.
Methods:
Adult male Wistar rats underwent unilateral intra-NAc administration of morphine (5, 10, 25, and 50 mmol) to assess dose-dependent antinociception using the tail-flick test. Orexinergic involvement was evaluated by intra-NAc injection of orexin-A (0.25, 0.5, 1, and 2 nmol), the orexin receptor type 1 (OX1R) antagonist SB334867 (3, 10, 30, and 100 nmol), or the orexin receptor type 2 (OX2R) antagonist TCS OX2 29 (3, 10, 30, and 100 nmol). To assess functional interactions, naloxone was administered prior to orexin-A, and SB334867 or TCS OX2 29 were given before morphine.
Results:
Intra-NAc injections of morphine and orexin-A produced significant and dose-dependent antinociceptive effects. Pre-treatment with SB334867 or TCS OX2 29 markedly reduced the analgesic responses induced by both morphine and orexin-A. Likewise, naloxone pre-treatment significantly attenuated orexin-A-evoked antinociception.
Conclusions:
These findings indicate a bidirectional interaction between opioidergic and orexinergic systems within the NAc in regulating acute nociception. The demonstrated functional crosstalk suggests that targeting orexinergic pathways may enhance endogenous analgesic mechanisms and could potentially reduce opioid requirements in clinical pain management.
